Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 8/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.32 |
| ▸ | CDC25B | P30305 | 6/20 | 0.32 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.31 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.31 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.31 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.30 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.30 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2174811 | 1.00 | SLC5A2 (0.34) | SLC5A2MCHR1PTPN1CDC25BSSTR5 | |
| SCHEMBL12407964 | 0.88 | SLC5A2 (0.36) | SLC5A2MCHR1SLC5A1 | |
| SCHEMBL2176303 | 0.86 | SLC5A2 (0.32) | SLC5A2MCHR1PTPN1CDC25B | |
| SCHEMBL2176298 | 0.86 | SLC5A2 (0.32) | SLC5A2MCHR1PTPN1CDC25B | |
| SCHEMBL1035412 | 0.85 | SLC5A2 (0.50) | SLC5A2SLC5A1 | |
| SCHEMBL29940875 | 0.85 | SLC5A2 (0.50) | SLC5A2SLC5A1 | |
| SCHEMBL499751 | 0.84 | SLC5A2 (0.40) | SLC5A2PTPN1CDC25BSLC5A1PTPN2 | |
| SCHEMBL20139485 | 0.82 | SLC5A2 (0.40) | SLC5A2PTPN1SLC5A1PTPN2PTPN11 | |
| SCHEMBL499844 | 0.80 | SLC5A2 (0.37) | SLC5A2SSTR5SSTR1SSTR2SSTR4 | |
| SCHEMBL1457373 | 0.80 | PTPN1 (0.37) | SLC5A2PTPN1CDC25BSSTR5SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076503-B1 | C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-7973012-B2 | C-phenyl glycitol compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20100022460-A1 | C-PHENYL GLYCITOL COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022460-A1 | C-PHENYL GLYCITOL COMPOUND | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885MCHR1 1232/4885PTPN1 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.